Free Trial
NASDAQ:CRDL

Cardiol Therapeutics Q3 2025 Earnings Results & Report

Cardiol Therapeutics logo
$0.98 -0.02 (-2.10%)
Closing price 03:59 PM Eastern
Extended Trading
$0.98 +0.01 (+0.61%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiol Therapeutics met analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.09 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Conference Call
6:00 PM ET

Cardiol Therapeutics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.09
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cardiol Therapeutics Q3 2025 Earnings FAQ

Cardiol Therapeutics (NASDAQ:CRDL) reported earnings of -$0.09 per share for Q3 2025, matching the consensus estimate of -$0.09. The report was announced on Thursday, November 13, 2025.

Cardiol Therapeutics Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (NASDAQ:CRDL) is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart.

The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure. These candidates are experimental and are not approved medicines.

View Cardiol Therapeutics Profile